SMO and neoplasm: Aberrant activation of the Hh signaling pathway by mutations in pathway components such as PTCH, SUFU, SMO, and amplifications of GLI1 and GLI2 drive tumor growth in basal cell carcinoma (BCC) [5], medulloblastoma [6], keratocystic odontogenic tumors [7, 8], meningioma [9–11], and ameloblastoma [12].